It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Polydeoxyribonucleotide (PDRN) is an agonist that selectively stimulates adenosine A2A receptor (ADORA2A), which suppresses inflammatory responses. Ischemia/reperfusion (I/R) injury plays a major role in the pathogenesis of ischemic stroke by inducing neuroinflammation. Therefore, this study aimed to investigate the therapeutic effects of PDRN in an in vitro I/R injury model. The in vitro model was established with differentiated Neuro-2a cells under oxygen and glucose deprivation condition. The cells were treated with PDRN for 24 h under reoxygenation condition. As the results of RNA-seq transcriptome analysis, CSF1, IL-6, PTPN6, RAC2, and STAT1 were identified of its relation to the effect of PDRN on inflammatory responses in the model. To further investigate therapeutic effects of PDRN, RT-qPCR, western blotting, LDH assay, and TUNEL assay were performed. PDRN significantly reversed the expression of genes and proteins related to inflammatory responses. The elevated ADORA2A expression by PDRN treatment downregulated JAK/STAT pathway in the model. Furthermore, PDRN inhibited neuronal cell death in the model. Consequently, our results suggested that PDRN alleviated inflammatory responses through inhibition of JAK/STAT pathway by mediating ADORA2A expression and inhibited neuronal cell death in the model. These results provide significant insights into potential therapeutic approaches involving PDRN treatment for I/R injury.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Yonsei University College of Medicine, Department and Research Institute of Rehabilitation Medicine, Seoul, South Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454); Yonsei University College of Medicine, Brain Korea 21 PLUS Project for Medical Science, Seoul, South Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454)
2 Yonsei University College of Medicine, Department and Research Institute of Rehabilitation Medicine, Seoul, South Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454); Yonsei University Wonju College of Medicine, Department of Rehabilitation Medicine, Wonju, South Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454)
3 Yonsei University College of Medicine, Department of Medicine, Seoul, South Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454)
4 Yonsei University Wonju College of Medicine, Department of Rehabilitation Medicine, Wonju, South Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454)
5 Yonsei University College of Medicine, Department and Research Institute of Rehabilitation Medicine, Seoul, South Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454)
6 Yonsei University College of Medicine, Department and Research Institute of Rehabilitation Medicine, Seoul, South Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454); Yonsei University College of Medicine, Brain Korea 21 PLUS Project for Medical Science, Seoul, South Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454); Yonsei University College of Medicine, Graduate Program of Biomedical Engineering, Seoul, South Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454); Yonsei University College of Medicine, Rehabilitation Institute of Neuromuscular Disease, Seoul, South Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454)
7 Eulji University School of Medicine, Department of Rehabilitation Medicine, Nowon Eulji Medical Center, Seoul, South Korea (GRID:grid.255588.7) (ISNI:0000 0004 1798 4296)